



DOCKET NO. H00498.70137


C1
13
10P
8/1/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jose Halperin
Serial No: 09/835,752
Conf. No: 5292
Filed: April 16, 2001
For: METHODS, PRODUCTS AND TREATMENTS FOR DIABETES
Examiner: A. DeCloux
Art Unit: 1644

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 19 day of March, 2003.


MaryDilys S. Anderson

Commissioner or Patents
Washington, D.C. 20231
Sir:

RECEIVED

MAR 31 2003

TECH CENTER 1600/2900

AMENDMENT

This is responsive to the Office Action mailed October 21, 2002. The corrected drawings, which have been corrected as required by the Official Draftsperson are filed herewith. Please amend the application as follows. Applicant has included herewith pages showing the markups of the specification and claims with insertions and deletions indicated by underlining and bracketing, respectively.

In the Specification

Please amend the specification as shown below.

Page 25, lines 5-12

C1
Site-directed Mutagenesis: Plasmid pK562-3 containing the cDNA of human CD59 (Philbrick, et al., 1990) was obtained from ATCC. Site-directed mutagenesis to substitute residue K41 or H44 for glutamine (Gln) was performed using the Altered Sites 11 system (Promega Corp. Madison, WI). The mutagenic primers used were 5'-GTC GTT GAA ATT ACA ATG CTC AAA CTG